Compare TYRA & CENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | CENTA |
|---|---|---|
| Founded | 2018 | 1955 |
| Country | United States | United States |
| Employees | N/A | 6000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2021 | N/A |
| Metric | TYRA | CENTA |
|---|---|---|
| Price | $28.28 | $38.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 4 |
| Target Price | ★ $47.50 | $36.75 |
| AVG Volume (30 Days) | ★ 807.7K | 278.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.60 |
| Revenue Next Year | N/A | $2.04 |
| P/E Ratio | ★ N/A | $13.52 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.98 | $25.97 |
| 52 Week High | $40.65 | $38.76 |
| Indicator | TYRA | CENTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 67.41 |
| Support Level | $27.40 | $31.21 |
| Resistance Level | $31.57 | N/A |
| Average True Range (ATR) | 1.98 | 0.97 |
| MACD | 0.26 | 0.22 |
| Stochastic Oscillator | 42.12 | 82.05 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.